The discovery of actionable mutations present within a subset of these tumours, most notably mutations in Epidermal Growth Factor Receptor (EGFR), and rearrangements of anaplastic lymphoma kinase (ALK) and V-Ros avian UR2 sarcoma virus oncogene homolog 1 (ROS1), has led to the development of a number of effective targeted treatment options for patients with advanced disease [1]. Here, ROS1 is linked to neoplasm.